Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Magnus Financial Group LLC purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the biotechnology company's stock, valued at approximately $276,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the second quarter valued at $426,000. State Street Corp increased its holdings in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Capricor Therapeutics in the third quarter valued at about $3,806,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the third quarter valued at about $161,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Trading Down 2.5 %

Shares of NASDAQ CAPR traded down $0.37 during midday trading on Thursday, hitting $14.53. 643,909 shares of the company's stock were exchanged, compared to its average volume of 888,677. The business's fifty day moving average price is $15.22 and its two-hundred day moving average price is $11.75. The company has a market cap of $660.68 million, a price-to-earnings ratio of -13.71 and a beta of 4.08. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective on the stock. Finally, Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.